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structures through neural connections, by injecting differ-
ent molecular species of human α-syn (monomers, oligom-
ers, fibrils) into the OB of wild-type mice. We found that 
non-fibrillar human α-syn is taken up very quickly by OB 
neurons. Within minutes to hours, it is also found in neu-
rons in structures connected to the OB. Conversely, when 
we injected bovine serum albumin used as a control protein, 
we found that it does not diffuse beyond the OB, is rarely 
taken up by OB cells, and does not transfer to other struc-
tures. Taken together, our results show that OB cells readily 
take up α-syn, and that monomeric and oligomeric, but not 
fibrillar, forms of α-syn are rapidly transferred to intercon-
nected structures within the timeframe we explored. Our 
results support the idea that α-syn can transfer along neural 
pathways and thereby contribute to the progression of the 
α-syn-related pathology.
Keywords α-Synuclein · Olfactory pathway · Olfactory 
bulb · Transfer · Microglia · Parkinson’s disease
Introduction
Parkinson’s disease (PD) is characterized by abnormal 
cytoplasmic inclusions, mainly composed of misfolded 
α-synuclein (α-syn) [27, 58] in neuronal soma (lewy  
bodies) and neurites (lewy neurites). α-Syn is a soluble 
protein, structured in α-helices when associated to mem-
branes. Under pathological conditions it oligomerizes and 
aggregates into fibrils arranged in β-rich sheet structures 
[16, 17, 57]. Despite the current lack of evidence that 
aggregated/misfolded α-syn is infectious between individu-
als [35], it has been proposed that aggregated/misfolded 
α-syn can behave in a prion-like fashion within the nerv-
ous system of one individual. This means that aggregated/
Abstract α-Synuclein (α-syn) is a protein prevalent in 
neural tissue and known to undergo axonal transport. Intra-
cellular α-syn aggregates are a hallmark of Parkinson’s dis-
ease (PD). Braak and collaborators have suggested that in 
people who are destined to eventually develop PD, α-syn 
aggregate pathology progresses following a stereotypic 
pattern, starting in the olfactory bulb (OB) and the gut. 
α-Synuclein aggregates are postulated to spread to inter-
connected brain regions over several years. Thus, propaga-
tion of the pathology via neural pathways can potentially 
explain how α-syn aggregates spread in PD. We have now 
studied if α-syn can transfer from the OB to other brain 
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misfolded α-syn can induce the native endogenous α-syn 
to adopt an abnormal conformation within the same cell. 
The misfolded α-syn is then released into the extracellular 
space and is taken up by a neighboring cell. Once inside 
the new cell, the misfolded α-syn can seed further α-syn 
misfolding and aggregation. Thereby the protein acts as 
a template for misfolding that transmits the disease pro-
cess from one cell to another. This intercellular transfer of 
misfolded α-syn is hypothesized to contribute to the pro-
gressive spread of lewy pathology in the nervous system 
in PD and other synucleinopathies [1, 11, 22, 30]. earlier 
post-mortem studies of lewy pathology in PD brains had 
led to the proposal that it gradually spreads throughout the 
nervous system following a predictable anatomical pat-
tern [6, 8]. Braak and co-workers [5] suggested that lewy 
pathology first develops in the olfactory bulb (OB), the 
anterior olfactory nucleus (AON), and in the dorsal motor 
nucleus of the vagus nerve, and based on neural connec-
tions to regions affected in later disease stages, they pro-
posed that the pathology spread along protracted unmy-
elinated axons to interconnected regions. We, and others, 
have suggested that this spreading results specifically from 
axonal transport of α-syn, followed by a cell-to-cell trans-
fer of misfolded α-syn to neighboring neurons. Numerous 
in vitro and in vivo studies show that α-syn can transfer 
between cells and seed aggregation in the recipient cell 
[2, 18, 19, 25, 29, 45, 50, 62]. Notably, the slow and fast 
intra-axonal transport of α-syn has also been well described 
in vitro [36, 56, 59], and studies using neurons in micro-
fluidic chambers demonstrate that fibrillar and oligomeric 
α-syn can be taken up from the medium and transported 
intra-axonally in both anterograde [25] and retrograde [61] 
directions. Finally, recent studies demonstrated that α-syn 
aggregates appear in widespread brain areas, 1–6 months 
after injection of preformed α-syn fibrils into the striatum 
or cortex of mice [43, 44]. This suggests axonal transport 
of an aggregation-prone α-syn, although it is not absolutely 
clear if the α-syn aggregates can transfer from one neu-
ron to another and develop in regions that are not directly 
connected to the injection sites. Moreover, the ability of 
α-syn to spread from anatomical regions suggested to be 
affected early in PD to brain areas that are impacted later 
on has so far not been explored. With the background that 
lewy pathology in olfactory structures and impairments 
in olfaction both appear early in PD [20, 21], we targeted 
the OB. For the first time, we stereotactically injected dif-
ferent molecular species (monomers, oligomers composed 
of soluble high molecular weight species, and fibrils) of 
recombinant human α-syn into the OB of normal mice. We 
then characterized in detail the transfer of α-syn to inter-
connected brain regions over 72 h. Our findings indicate 
that α-syn monomers and oligomers are most rapidly and 
readily transferred from the injection site to interconnected 
brain regions. We observed a particular pattern of spread 
that matches known neural connections in the brain, but we 
cannot conclude with certainty that this transfer occurred 
by classical axonal transport. Our results supports the 
notion that transport of α-syn oligomers between inter-
connected regions might be important in the spreading of 
α-syn pathology between brain regions in PD.
Materials and methods
Animals
We purchased C57Bl/6J 3-month-old female mice from 
Charles river laboratories and housed them six per cage 
under a 12-h light/12-h dark cycle with access to food and 
water ad libitum. The housing of the animals and all proce-
dures were in accordance with the international guidelines 
and were approved by the Malmö-lund ethical Committee 
for Animal research.
Synthesis of different molecular species of recombinant 
wild type human α-syn
We expressed recombinant S-tagged wild-type (WT) 
human α-syn in Escherichia coli strain Bl21 (De3) 
(Stratagene) and purified it as described previously [26]. 
We determined α-syn concentration by spectrophotometry 
using an extinction coefficient of 5,960/M/cm at 280 nm. 
Pure α-syn (0.5 mM) in 50 mM Tris–HCl, pH 7.5, 150 mM 
KCl was filtered through sterile 0.22 μm filters and stored 
at −80 °C.
We obtained α-syn oligomers by incubating soluble 
S-tagged WT α-syn in 50 mM Tris–HCl (pH 7.5, 150 mM 
KCl) at 4 °C for 7 days without shaking. We separated oli-
gomeric α-syn from monomeric α-syn by size exclusion 
chromatography (Superose 6 Hr10/30, ge Healthcare). 
To achieve fibril assembly, we incubated soluble S-tagged 
WT α-syn under continuous shaking in an eppendorf Ther-
momixer set at 600 rotations/min and 37 °C. We assessed 
the nature of the oligomeric and fibrillar species using a 
Jeol 1400 transmission electron microscope (Jeol ltd.) fol-
lowing adsorption of the samples onto carbon-coated 200-
mesh grids and negative staining with 1 % uranyl acetate. 
The images were recorded with a gatan Orius CCD camera 
(gatan).
Fluorescent labeling
Monomeric and oligomeric S-tagged α-syn assemblies 
in 50 mM Tris–HCl (pH 7.5, 150 mM KCl) were buffer 
exchanged using NAP10 desalting columns (ge Health-
care) to phosphate buffered saline (PBS) buffer. We 
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performed α-syn labeling with ATTO-550 NHS fluoro-
phore following the manufacturer instruction (ATTO-
Tec gmbh) using a protein:dye ratio of 1:2. We removed 
unreacted fluorophore using NAP10 desalting columns. 
We centrifuged α-syn fibrils at 16,000g for 10 min (min) 
and resuspended them twice in PBS and labeled them as 
a
20 min0 1.5h 3h 12h 72h
20 min 72h3h0
3h0





DAPI / Alexa-488 3h
OB
AON
Oligomeric tα-syn Fibrillar tα-synb Monomeric tα-syn
c
Fig. 1  experimental design and controls of diffusion. a experimen-
tal design. In wild-type mice, we stereotactically injected α-synuclein 
(α-syn) into the olfactory bulb (OB), the lateral ventricle (lV) or at 
the level of subarachnoid space dorsal to the OB. Different molecu-
lar species of human recombinant α-syn tagged with ATTO-550 and 
S-tag (tα-syn) were injected: monomeric, oligomeric, or fibrillar tα-
syn; or bovine serum albumin tagged with ATTO-550 (tBSA); or 
unbound ATTO-550 or Alexa-488 alone as control. We killed mice 
20 min, 1.5, 3, 12 or 72 h after injection for histology. b Characteriza-
tion of recombinant tα-syn. Negatively stained transmission electron 
micrographs of monomeric, oligomeric and fibrillar tα-syn. Oligomer 
samples are homogeneous, and do not contain any α-syn fibrils. Scale 
bar represent 100 nm. c Photographs of the injected region in the OB 
3 h after injection of unbound ATTO-550 or Alexa-488 (dissolved in 
PBS) into the OB of mice. The images illustrate how far the injected 
solution diffused in the neural tissue. Left panel is a montage of coro-
nal sections of a brain injected with unbound ATTO-550 (inter-sec-
tion interval = 450 μm). Three hours after injection, ATTO-550 dif-
fused from the injection site to lateral layers of the OB, and until the 
very anterior part of the AON, but not further. Scale bar 1 mm. Right 
panel is a low magnification picture of a sagittal section of a brain 
injected with Alexa-488. At 3 h after injection, Alexa-488 diffused 
from the injection site to the posterior part of the OB, the accessory 
olfactory bulb (AOB) and until the very anterior part of the anterior 
olfactory nucleus (AON), but not further. Dashed line represent the 
limit of Alexa-488 diffusion. Scale bar represent 500 μm. The white 
asterisk marks the injection site
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described above. We removed unreacted fluorophore by 
centrifugation at 16,000g for 10 min and then resuspended 
the pelleted fibrils twice in PBS. In the rest of the article, 
we have denoted recombinant α-syn tagged with ATTO-
550 and S-tag “tα-syn”. lyophilized BSA was purchased 
form Sigma (ref A9418), dissolved in PBS at 5 mg/ml and 
labeled with ATTO-550 dye using a protein:dye ratio of 
1:2 following the same procedure as described for soluble 
tα-syn. Similarly, we have abbreviated BSA tagged with 
ATTO-550 as “tBSA”.
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As control solutions, we will use unbound ATTO-550 
and Alexa-488 (unbound to proteins). To obtain them, the 
NHS groups of ATTO-550 and Alexa-488 NHS (5 mM) 
were reacted with Tris–HCl (pH 7.5, 200 mM) as a primary 
amine source at room temperature for 3 h. The solution was 
then diluted to 200 μM in PBS and stored them at −80 °C.
Stereotactic injections
We anesthetized 105 mice (3-month-old) with isoflurane/
oxygen/nitrogen mixture, and stereotactically injected tα-
syn or tBSA into the OB, or other intracranial sites (control 
injections) as specified below. We performed the stereo-
tactic injections using a glass capillary attached to a 10 μl 
Hamilton microsyringe, and injected 0.8 μl of protein or 
fluorophore solutions unilaterally in the OB (coordinates: 
AP: +5.4 mm, L: −0.75 mm, DV: −1 mm relative to 
bregma and dural surface).
The solutions we injected contained monomeric, oli-
gomeric, fibrillar tα-syn, monomeric untagged α-syn or 
tBSA at a concentration of 1 mg/ml in sterile PBS. We 
perfused the mice 20 min, 1.5, 3, 12 or 72 h after injec-
tion and collected brains (4 mice per group; Fig. 1a; sup-
plementary Table 1). To examine how far injected vehicle 
(containing no protein) can diffuse, we also injected mice 
with unbound ATTO-550 (9 mice) or unbound Alexa-488 
in PBS (1 mg/ml, 6 mice) into the OB and perfused them 
at one of three time points (20 min, 3, 72 h).
To control for the possible spread of tα-syn within the 
brain via cerebrospinal fluid, we performed control injec-
tions of monomeric tα-syn in the subarachnoid space 
(on the top of the OB after breaking the dura mater; AP: 
+5.4 mm, L: −0.75 mm, DV: 0 mm relative to bregma 
and dural surface) or into the lateral ventricle (lV, AP: 
+0.74 mm, L: −0.6 mm, DV: −2.2 mm). We injected three 
animals per location and perfused these mice 3 h after 
injection. Following initial pilot experiments, we chose the 
volume of solution we injected so that it resulted in suf-
ficient amounts of protein in the OB to allow the study of 
transport, but without giving rise to significant diffusion 
to other brain structures. Due to retrograde leakage of the 
injected protein along the injection capillary tract, we had 
to exclude one mouse in each of the following groups: 
monomeric tα-syn 1.5 h, oligomeric tα-syn 1.5 h, mono-
meric tα-syn 3 h and oligomeric tα-syn 3 h.
Immunohistochemistry and analysis
Preparation of the tissue
At 20 min, 1.5, 3, 12 or 72 h after injection, we anesthe-
tized mice with sodium pentobarbital and perfused them 
transcardially with 0.9 % saline followed by 4 % PFA in 
phosphate buffer. We dissected the brains, post-fixed them 
for 2 h in 4 % PFA and placed them in 30 % sucrose in 
phosphate buffer. We stored the brains at 4 °C until section-
ing. We cut the entire brains into 30 μm free-floating coro-
nal sections on a freezing microtome, and stored them in 
antifreeze solution at 4 °C until immunostaining. To control 
how far a protein-free solution could diffuse, we cut some 
brains injected with unbound Alexa-488 into 30 μm free-
floating sagittal sections, and brains injected with unbound 
ATTO-550 into 30 μm free-floating coronal sections.
Diaminobenzidine (DAB) stainings
We stained coronal free-floating sections using primary 
antibodies anti-human α-syn syn211 (monoclonal raised 
in mouse, 1:500, Invitrogen) or anti-BSA (raised in rabbit, 
1/1,000, Invitrogen) or anti-S-tag (1/1,000, Delta Biolab), 
and secondary antibodies biotinylated (Horse anti-mouse, 
1/200, Vector lab; Donkey anti-rabbit 1/200, Abcam; goat 
anti-rabbit, 1/200, Vector lab). For the detection of the 
antibody with DAB, we used a standard peroxidase-based 
method (Vectastain ABC kit, and DAB kit, Vector labora-
tories) with nickel enhancement. S-tag staining was carried 
out on one mouse per group at 1.5 h to confirm our obser-
vations from syn211 staining. Sections were then counter-
stained by haematoxylin. We analyzed these sections by 
conventional light microscopy (eclipse 80i microscope; 
Nikon).
Immunofluorescence staining
We stained coronal free-floating sections with primary 
antibodies anti-human α-syn syn211 (monoclonal raised 
in mouse, 1:500, Invitrogen), anti-Tuj1 (polyclonal raised 
in rabbit, 1/2,000, Covance), anti-Tuj1 (and monoclo-
nal raised in mouse, 1/5,000, Covance), anti-BSA (raised 
Fig. 2  Tα-syn is taken up by OB cells less than 20 min after injec-
tion in the OB. Huα-syn- (stained with syn211 antibody) and BSA-
staining in the OB, 20 min after injection of tα-syn, tBSA or ATTO-
550 into the OB: a low magnification pictures of the ipsilateral OB 
(gl/Mit/gCl) (scale bar 50 μm), or high magnification pictures 
(scale bar 10 μm) of glomerular layer (gl) (b), mitral layer (Mit) 
(c), and granular cell layer (gCl) (d) of the ipsilateral OB. At 20 min 
after injection of monomeric, oligomeric and fibrillar tα-syn into the 
OB, we detected huα-syn-positive cells in various layers of the OB 
(gl, Mit, and gCl), but no BSA-positive cells in the OB injected 
with tBSA. A diffuse BSA-staining was observed in extracellular 
space. To control for specificity of our immunohistochemistry proto-
col, sections from groups that were injected with ATTO-550 into the 
OB were stained for huα-syn, and did not reveal any huα-syn-positive 
staining. A white arrow points examples of huα-syn-positive cells. 
e Uptake of injected α-syn at 20 min: number of huα-syn positive 
mitral cells in the ipsilateral OB at 20 min (H = 6.053, P < 0.04, post 
hoc test: monomers/fibrils P < 0.05). Scatter plots show data from 
individual mice
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Fig. 3  Tα-syn is localized 
within the somata of mitral cells 
in the OB 20 min after injec-
tion. We stained brain sections 
by immunofluorescence for 
Tuj1 (green), a neuronal marker, 
and for huα-syn or BSA. Tα-
syn was identified both by its 
ATTO-550 fluorescent tag (red) 
and by the huα-syn (syn211 
antibody) staining (blue). Simi-
larly, in groups injected with 
BSA, the BSA was detected 
both by its ATTO-550 tag (red) 
and by BSA staining (blue). 
Confocal three-dimensional 
reconstructions (large panels) 
show ATTO-550 signal (red) 
colocalized with huα-syn 
staining (blue) within mitral 
cells (tuj1, green) in the OB of 
mice injected with monomers 
(a), oligomers (b) and fibrils 
(c), indicating that these cells 
contain huα-syn. We also occa-
sionally detected BSA-positive 
punctae within Tuj1-positive 
mitral cells in mice injected 
with BSA (d). Smaller panels 
are confocal plans showing 
tuj1 (green), ATTO-550 (red), 
huα-syn or BSA (blue) staining, 
and merged pictures of green 
and red channels. Scale bars 
represent 10 μm in every panel. 
White arrowheads point to tα-
syn punctae
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in rabbit, 1/1,000, Invitrogen), anti-Iba1 (raised in rab-
bit, 1:500, Wako/Nordic labs) and with the appropriate 
secondary antibodies Alexa-488 anti-rabbit, Alexa-488 
anti-mouse, Alexa-647 anti-mouse, Alexa-647 anti-rabbit 
(raised in goat, 1:400, Invitrogen). We analyzed these spec-
imens with a confocal laser microscope Zeiss lSM 510, 
equipped with Ar and HeNe lasers.
Cell quantifications
We quantified the number of hu-α-syn positive cells in 
structures positive for hu-α-syn (diaminobenzidine stain-
ing) using a computer-assisted mapping and cell quantifica-
tion program (Stereo Investigator, MBF Bioscience, Willis-
ton, USA) coupled to a Zeiss Imager M2 microscope (Carl 
Zeiss Microimaging, göttingen, germany). We analyzed 
all the positive structures in four animals per group, at 
40× magnification at 1.5 h time point; the OB and the piri-
form cortex of four animals per group at 20 min time point 
and at every time point from 20 min to 3 h, respectively. 
In the OB, only mitral cells were analyzed. every positive 
cell (exhibiting staining in the whole cell body, or punc-
tate within the cell body) was counted in each structure 
on a determined number of sections per structure, spaced 
by 240 μm, and distributed along the rostrocaudal axis at 
equivalent locations in each animal. Then we calculated the 
total number of cells detected per structure. Kruskal–Wallis 
tests and post hoc Dunn’s multiple comparison analysis of 
the counting in the OB were performed on n = 4 per group, 
using Prism 6.0, graphpad.
Results
Control of the composition and the stability of tα-syn 
preparations and experimental controls for stereotactic 
injections
Prior to injection, the monomeric, oligomeric and fibrillar 
states of recombinant α-syn were confirmed by transmis-
sion electron microscopy (Fig. 1a). To define the size of our 
oligomers, we performed size exclusion chromatography. 
We found that they are composed of soluble high molecu-
lar species, eluted at 2 MDa by this method (supplementary 
Fig. 1). It is worth noting that size exclusion chromatog-
raphy does not allow an accurate measurement of the size 
of the protein since the mobility of the protein in the col-
umn depends also on its conformation and its charge [24]. 
Therefore, we cannot claim to know the precise size of our 
oligomers.
We also confirmed the stability of our different α-syn 
assemblies over 72 h period (supplementary Fig. 2). After 
a 72 h incubation at 37 °C, we found that the monomeric 
α-syn remains monomeric and soluble as shown by size 
exclusion chromatography (supplementary Fig. 2a, c) and 
sedimentation assay (supplementary Fig. 2e); oligomeric 
α-syn does not polymerize or disassemble (size exclusion 
chromatography, supplementary Fig. 2b, d), and fibrillar α-
syn fibrils incubated in serum remain fibrillar (supplemen-
tary Fig. 2f).
We then controlled that our injections successfully tar-
geted the rostrodorsal OB (supplementary Fig. 3a, b). To 
establish that any spreading of α-syn from the OB to other 
brain regions that we might observe was not due to non-
specific diffusion or leakage from the injection site, we per-
formed a series of important control experiments. Thus, to 
check that 0.8 μl of solution that we injected into the OB 
does not diffuse to other structures, we injected unbound 
ATTO-550 or Alexa-488 in PBS at the same coordinates 
used for tα-syn injection. We euthanized mice at different 
time points after injection (20 min, 3, and 72 h), dissected 
and cut brains sagittally or coronally to be able to moni-
tor how far the injected solution diffused. We observed 
the maximum diffusion area at 3 h (Fig. 1c). At this time 
point, we observed (in sagittal and coronal sections) that 
the injected solution had diffused from the injection site in 
the OB to the anterior part of the AON. After 72 h, we only 
detected the control fluorophore in the central part of the 
OB (supplementary Fig. 3c).
Neurons take up recombinant monomeric, oligomeric and 
fibrillar α-syn in less than 20 min after injection into the 
olfactory bulb
We sacrificed mice injected with tα-syn (monomers, oli-
gomers or fibrils); tBSA or unbound ATTO-550 (as con-
trols in the OB) 20 min after injection. Brain sections 
were stained with anti-human α-syn (huα-syn) antibody 
(syn211) or with anti-BSA antibody. In mice injected 
with monomeric, oligomeric and fibrillar tα-syn, we iden-
tified huα-syn-positive cells in different layers of the OB 
(Fig. 2a), i.e. the glomerular layer (gl, Fig. 2b), mitral 
cell layer (Mit, Fig. 2c), and in granule cell layer (gCl, 
Fig. 2d). The mitral cell layer contains the relay cells of the 
OB that project to central olfactory structures [49]. In con-
trast, no obvious BSA-positive signal in DAB was detected 
in OB cells (Fig. 2a–d). Instead, a diffuse signal in the 
extracellular space was seen. We also used the syn211 anti-
body to stain sections from brains injected with unbound 
ATTO-550. As expected, mice injected with only unbound 
ATTO-550 did not stain with the syn211 antibody and 
thus were negative for huα-syn (Fig. 2a–d; supplementary 
Table 2). Quantification, in DAB stained sections, revealed 
similar numbers of huα-syn positive mitral/tufted cells in 
the OB in groups injected with oligomers and monomers. 
The number of huα-syn positive mitral/tufted cells was, 
562 Acta Neuropathol (2013) 126:555–573
1 3


































BSA 1.5hhuα-syn 1.5h huα-syn 1.5h huα-syn 1.5h
563Acta Neuropathol (2013) 126:555–573 
1 3
however, significantly lower in the group injected with 
fibrils (Fig. 2e).
We detected tα-syn both by its ATTO-550 fluorescent 
tag (in red), and by huα-syn (syn211) immunostaining (in 
blue) using confocal microscopy (Fig. 3a–c). Similarly, we 
detected injected tBSA by visualizing its’ ATTO-550 fluo-
rescent tag (in red), and by BSA immunostaining (in blue) 
(Fig. 3d). We detected neuronal cells by staining with a 
Tuj1 antibody (in green). In the mice injected with huα-syn 
monomers, oligomers or fibrils, we found that some Tuj1-
immunoreactive mitral/tufted cells (Fig. 3a–c), granule 
cells, and periglomerular cells (data not shown), exhibited 
both ATTO-550 fluorescence and syn211-immunoreac-
tivity confirming that they had taken up huα-syn. In mice 
in which we had injected monomers or oligomers into the 
OB, the syn211/ATTO-550 signal appeared both as a dif-
fuse staining and as punctae within the cell bodies and pro-
cesses of Tuj1-positive cells (Fig. 3a, b). In mice injected 
with fibrillar tα-syn, Tuj1-positive cells contained huα-syn 
rarely (Fig. 3c), consistently with what we observed in our 
quantifications (Fig. 2e). In mice injected with tBSA, very 
rare Tuj1-positive cell contained BSA-positive punctae 
(Fig. 3d).
These data demonstrate that mitral/tufted cells, periglo-
merular cells as well as granular cells readily take up mon-
omeric and oligomeric tα-syn. Fibrillar tα-syn is also taken 
up, but to a much lesser extent within the time frame of the 
experiment. The high degree of neuronal uptake of injected 
tα-syn seems to be specific, as our control protein BSA was 
rarely taken up by neurons (Figs. 2a–d, 3d).
Monomeric and oligomeric tα-syn appears in 
interconnected brain regions soon after injection into the 
olfactory bulb
20 min post‑injection
After injecting monomeric or oligomeric tα-syn into the 
OB, we found huα-syn-positive cells in the ipsilateral AON 
and occasionally (in one animal out of 4) in the ipsilateral 
frontal cortex (FC). After fibrillar tα-syn injections, we 
observed huα-syn-positive cells in the ipsilateral anterior 
AON only, in two mice out of four, event occurrence are 
summarized in supplementary Table 2, and immunohis-
tochemistry results in supplementary Fig. 4. We did not 
observe BSA-positive signal in DAB in any non-OB brain 
region in control injections of tBSA.
1.5 h post‑injection
At the 1.5 h time point, in mice injected with monomeric 
or oligomeric tα-syn in the OB, we detected huα-syn-
positive cells in several additional brain ipsilateral-regions: 
namely the AON, the FC, the tenia tecta (TT), the olfac-
tory tubercle (OTu), the piriform cortex (PC), the stria-
tum and the amygdala. Huα-syn-positive cells were also 
present in the contralateral hemisphere, specifically in 
the FC and the AON (Fig. 4). The huα-syn-positive cells 
displayed both a diffuse perikaryal staining as well as a 
punctae staining pattern. Importantly, in ipsilateral struc-
tures located distant from the OB, e.g. as the striatum and 
the amygdala, we detected a few huα-syn-positive cells (a 
few cells per region) (Fig. 4). Brains injected with fibrillar 
tα-syn presented huα-syn-positive cells in the ipsilateral 
OB only (Fig. 4; supplementary Fig. 5a), suggesting that 
the fibrillar tα-syn was not transferred to any other brain 
region within 1.5 h. In brains given control injections of 
tBSA, we found no BSA-positive cells either inside or 
outside the OB. We only observed a diffuse extracellular 
staining in the injected OB and in the anterior part of the 
AON. In supplementary Table 3, we present details of the 
distribution of huα-syn- and BSA-positive staining in each 
group at 1.5 h. The quantification of huα-syn positive cells 
in groups injected with monomers and oligomers showed 
that the cells in anterior brain regions frequently exhibited 
huα-syn transfer. By contrast, in brain regions located fur-
ther away from the OB (e.g. amygdala) the rate of huα-
syn transfer was low (Fig. 5a–d). Schematic drawings of 
coronal brain sections in supplementary Fig. 6a–c depict 
the overall load of huα-syn-positive cells in the different 
brain regions.
Importantly, to confirm our data from huα-syn staining 
at 1.5 h time point, we also performed a staining directed 
against the S-tag of tα-syn. In each group of mice, we 
observed S-tag-positive cells in the same structures as with 
huα-syn staining. Thus the results obtained from S-tag 
detection are identical to the one from huα-syn staining 
(supplementary Fig. 7). Moreover, we confirm that the 
uptake by neurons and the transfer of huα-syn are not due 
to presence of the tags on huα-syn: injections of untagged 
monomeric huα-syn led the same distribution pattern as 
injections of tagged protein (supplementary Fig. 8; supple-
mentary Table 3).
Fig. 4  Transfer of tα-syn to other structures 1.5 h after injection 
into the OB. Images illustrating huα-syn or BSA staining at high 
magnification (scale bar 10 μm) in various brain areas. We detected 
huα-syn-positive cells in various brain structures 1.5 h after the injec-
tion of monomeric and oligomeric tα-syn into the OB. We observed 
huα-syn-positive cells in the ipsi- and contralateral anterior olfactory 
nucleus (ipsi/contra AON), in ipsi- and contralateral frontal cortex 
(ipsi/contra FC), in ipsilateral tenia tecta (ipsi TT), olfactory tubercle 
(ipsi Otu), piriform cortex (ipsi PC), amygdala (ipsi Am) and striatum 
(ipsi Str). On the contrary, we detected huα-syn-positive cells only in 
the ipsilateral OB when we injected fibrillar tα-syn. tBSA injected as 
a control protein into the OB, was not detected in the brain, except in 
the injected OB where we observed only a diffuse staining in extra-
cellular space, but no obvious BSA-positive cell
◂
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3 h post‑injection
3 h after injection of tα-syn monomers and oligomers into 
the OB, we still detected huα-syn-positive cells in some of 
the structures mentioned above (the ipsilateral AON, FC, 
TT, OTu, PC, and in the contralateral AON for monomers 
only). However, in contrast to the 1.5 h time point, we no 
longer found any huα-syn-positive cells in the ipsilateral 
amygdala, striatum and in contralateral FC (supplemen-
tary Fig. 9a; supplementary Table 4). In mice injected 
with fibrillar tα-syn, we still detect huα-syn-positive 
cells in the OB only. By contrast, mice receiving control 
injections of tBSA exhibited only diffuse BSA staining in 
ipsilateral OB and in the very anterior part of ipsilateral 
AON, and we observed no positively stained cell bod-
ies in any brain region (data not shown). In Fig. 6a, we 
present a schematic drawing summarizing the progres-
sion of protein spread in the brain within the time frames 
we examined. Quantification of the number of positive 
cells in the piriform cortex show that the highest rate of 
transfer of monomeric and oligomeric tα-syn occurred 
within 1.5 h, followed by a strong decrease in the num-
ber of positive cells after 3 h (Fig. 5e). In supplementary 












































































































































Fig. 5  Quantifications of huα-
syn-positive cells in different 
structures 1.5 h after injection 
into the OB. a Number of posi-
tive mitral cells in the ipsilateral 
OB at 90 min (H = 9.846, 
P < 0.01, post hoc test: mono-
mers/fibrils P < 0.01). Positive 
cells in the ipsilateral anterior 
olfactory nucleus (iAON), 
ipsilateral frontal cortex (iFC) 
(b); ipsilateral tenia tecta (iTT), 
olfactory tubercle (iOTu), piri-
form cortex (iPC), and striatum 
(iStr) (c); ipsilateral amygdala 
(iAm) and contralateral tenia 
tecta (cTT), anterior olfactory 
nucleus (cAON) and frontal cor-
tex (cFC) (d). e Time evolution 
of α-syn transfer and clearance 
in the ipsilateral piriform cortex. 
Scatter plots show data from 
individual mice. Black symbols 
represent animals that were 
excluded due technical issues 
during injection
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sections showing the distribution of huα-syn-positive cells 
throughout the brain.
To control that the tα-syn we detected in brain regions 
far from the OB was not likely to be due to diffusion of 
the injected solution via the cerebrospinal fluid, we injected 
the same volume (0.8 μl) of monomeric tα-syn in the lat-
eral ventricle (lV), or on the top of the OB, into the sub-
arachnoid space. We killed mice 3 h after injection, and 
performed huα-syn immunostaining. We found huα-syn-
positive cells around the injection site in the overlying 
cortex when the solution was injected into the lV. None of 
the brain structures mentioned above exhibited huα-syn-
positive cells (AON, FC, PC, striatum, amygdala shown in 
supplementary Fig. 9b; supplementary Table 5). When we 
injected tα-syn on the top of the OB (in the subarachnoid 
space, we observed huα-syn-positive staining 3 h later only 
on the superficial part of the olfactory nerve at the level of 
injection. Thus we found no huα-syn-positive cells in the 
brain (negative staining in the OB, AON, FC, PC, striatum, 
amygdala shown in supplementary Fig. 9b; supplementary 
Table 5). These controls strongly suggest that tα-syn pre-
sent in cells far from the OB is not the result of a diffusion 
of injected tα-syn through the cerebrospinal fluid. Taken 
together, our results suggest that after injection into the 
OB, monomeric and oligomeric tα-syn is taken up by neu-
rons locally and rapidly spreads from the OB to other brain 
structures.
More than 12 h after injection into the olfactory bulb, 
α-synuclein is present in neurons and microglia locally, as 
well as in microglia in interconnected brain regions
We also investigated the localization of tα-syn at two later 
time points, 12 and 72 h post-injection.
12 h post‑injection
After injections of monomers and fibrils into the OB, we 
detected tα-syn in cells with a microglia-like shape in the 
ipsilateral OB and FC; and occasionally in the AON, in one 
to two animals out of four. After injection of oligomers, we 
observed huα-syn-positive cells with microglia-like shape 
in the ipsilateral OB, FC and AON (Fig. 6b; supplementary 
Table 6). Interestingly, in the mice that received injections 
of oligomers or fibrils into the OB, we also identified huα-
syn-positive mitral and tufted cells, based on their shape 
and precise localization using DAB staining (Fig. 6b, repre-
sentative sketches in supplementary Fig. 6b, c).
We confirmed the presence of tα-syn in the perikarya 
of microglia in the OB by immunofluorescent staining for 
Iba1 after injection of monomeric (Fig. 7a), oligomeric 
(Fig. 7b) and fibrillar tα-syn (Fig. 7c). rarely we found 
microglial cells containing BSA-positive punctae (detected 
with its ATTO-550 tag) (Fig. 7d) 12 h after injection of 
tBSA.
72 h post‑injection
At 72 h after injection of tα-syn monomers, oligomers and 
fibrils, we observed heavily huα-syn-positive microglia 
cells in the ipsilateral OB and FC, as well as the ipsilat-
eral AON (Fig. 6c; supplementary Table 7). Again, we con-
firmed the presence of tα-syn (detected using ATTO-550 
tag) in the perikarya of microglia in the OB by immuno-
fluorescence after injection of tα-syn (Fig. 8d).
Recruitment of microglia in the OB 1.5 h after injection  
of tα‑syn
The first microglial cells appear in the OB around the injec-
tion site 1.5 h after injection of oligomeric tα-syn. While 
we could not detect Iba1-positive cells at 20 min (Fig. 8a), 
we observed tα-syn in the perikarya of microglia in the 
OB at later timepoints, from 1.5 to 72 h after injection 
(Fig. 8b–d).
Discussion
Here we demonstrate that huα-syn is taken up by neurons 
in the OB and can also be rapidly transferred to intercon-
nected brain regions. Specifically, local OB interneurons as 
well as mitral/tufted cells (relay cells of the OB that pro-
ject to further olfactory structures) readily take up mono-
meric and oligomeric huα-syn. The same neurons also take 
up fibrillar huα-syn, but to a much lesser extent. The OB 
cells also take up tBSA, but to a lesser degree, suggesting 
that monomeric and oligomeric huα-syn are readily taken 
up and subject to transfer to other brain regions. Consistent 
with previous observations made in vitro [41], α-syn low 
molecular species are rapidly taken up resulting in some 
OB cells being positive for huα-syn already 20 min after 
injection.
Non-specific/passive diffusion probably plays a minor role 
in spreading of α-synuclein in the brain
We performed different control injections and the results 
showed that it is highly unlikely that the injected material 
diffuses away from the OB via the brain parenchyma or the 
cerebrospinal fluid and thereby contributes to the spread of 
injected huα-syn to other brain regions. Therefore the huα-
syn we observed in neurons in brain regions distant from 
the OB is more likely to have been transported intracel-
lularly via neural projections, considering the pattern of 
transfer to structures interconnected with the OB.
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regarding the different molecular species of huα-syn we 
used, we observed clear differences in the transfer of fibrils 
and monomers/oligomers. We found that monomers and 
oligomers are taken up by neurons in the OB and are rap-
idly transported to other brain regions. In contrast, fibrils 
are taken up by fewer neurons in the OB and they are not 
transferred at detectable levels to other brain regions within 
72 h.
In vitro, the internalization of fibrils by neurons is 
slower than that of soluble α-syn and can take several hours 
[41]. This relatively slow uptake of fibrils, combined with 
a rapid and efficient clearance of extracellular huα-syn by 
microglia, could limit the load of fibrils that are taken up 
by neurons.
Alternative spreading mechanisms to intra-axonal transport
Our data suggest that the injected huα-syn does not spread 
via the cerebrospinal fluid. We cannot, however, rule out 
the involvement of other mechanisms in huα-syn spread 
from the OB. entry of huα-syn into the blood circulation 
by physically damaged vessels at the injection site, and 
transport of huα-syn via blood vessels is one such option. 
In the mouse, huα-syn injected intravenously has a half-life 
of about 1 h [37]. However, there is no spread to structures 
that are not connected via neural pathways to the OB, sug-
gesting that vascular transfer is not involved. Another pos-
sibility is huα-syn is engulfed by microglial cells [4, 64] 
that then migrate from one brain region to another. If the 
huα-syn is not successfully degraded by the microglia 
it is conceivable that it is released into the extracellular 
space and then is taken up by adjacent cells. Once again, 
however, then one would not expect to find huα-syn posi-
tive neurons only in regions directly connected via neural 
pathways to the OB. Finally, two other alternative mecha-
nisms to microtubule-dependent intracellular transport that 
could explain the specific pattern in interconnected regions 
need to be considered. either simple diffusion of huα-syn 
within the neuronal cytoplasm could play a role, or myo-
sin-actin-dependent transport [9], that is reported to sup-
port transport (of organelles) within axons and dendrites, is 
operative. For both these mechanisms, however, the speed 
of transport is too low to explain our observations. Further-
more, short actin filaments are more likely to contribute to 
short-distance intra-neuronal transport as opposed to long-
range axonal transport [9].
Direction of α-synuclein transfer
Several in vitro and in vivo studies strongly suggest that 
α-syn can be released by cultured cells or neurons in vivo 
and taken up from the culture medium or from extracellular 
compartment by neighboring cells [2, 19, 25, 29]. In addi-
tion, other in vitro studies have demonstrated that α-syn is 
transported within the axon of a recipient neuron in both 
anterograde and retrograde directions [25, 61]. Therefore, 
if the spread of huα-syn we observe is due to an axonal 
transport from the OB to interconnected region, transport 
along axons in both directions, combined with cell-to-cell 
transfer at synaptic sites, could explain why we observed 
huα-syn in brain regions outside the OB.
First, with this hypothesis in mind, let us consider that 
huα-syn undergoes anterograde axonal transport from the 
OB in our paradigm (see Fig. 9), a notion consistent with 
the dual-hit hypothesis [31]. Almost every structure where 
we detected huα-syn-positive neurons receives direct 
axonal projections from OB mitral/tufted cells (ipsilateral 
AON, TT, OTu, PC, amygdala; [12, 28, 33, 48]). Thus, it is 
possible that the injected huα-syn underwent anterograde 
transport from the OB to these structures within the axons 
of mitral/tufted cells, and then transferred from the axon 
termini to the target neurons. regarding the brain struc-
tures that lack direct axonal projections from the OB but 
that still exhibited huα-syn-positive neurons (ipsilateral 
striatum, contralateral AON and both ipsilateral and con-
tralateral FC), anterograde transport in two steps could 
explain the spread we observed. For example, the huα-
syn might have been transported via the PC/amygdala to 
the striatum, followed by a cell-to-cell transfer to striatal 
neurons.
Second, still in the light of a possible intra-axonal trans-
fer, huα-syn could also have been transported retrogradely 
from the OB to connected brain regions. The OB receives 
projections from almost all the structures where we 
detected huα-syn, namely the AON bilaterally [34, 54], FC 
[14], ipsilateral PC and OTu [47] and the ipsilateral TT [15, 
52]. Thus, retrograde transport along axons to cell bodies 
Fig. 6  Temporal evolution of tα-syn presence in the brain after 
injection in the OB. a Drawings representing schematic horizontal 
sections of the brain with the different regions exhibiting huα-syn-
positive cells or a diffuse BSA-staining at different time points after 
protein injection in the OB. b BSA and huα-syn staining 12 h after 
injection in the OB. We detected huα-syn-positive cells in the ipsi-
lateral OB, and FC after injection of monomeric, oligomeric and 
fibrillar tα-syn, as well as in the ipsilateral AON after injection of oli-
gomers. On the contrary, we did not find BSA-positive cells in the 
brain 12 h after tBSA injection in the OB. Huα-syn-positive cells 
appeared to be either mitral/tufted cells, located in the external plexi-
form (ePl) and mitral cell (Mit) layers of the OB (in groups injected 
with oligomers or fibrils, grey arrows), or displayed the morphology 
of microglial cells (in groups injected with monomers, oligomers or 
fibrils; black arrows). Scale bar represent 25 μm. c Huα-syn- and 
BSA-staining 72 h after injection in the OB. Huα-syn-positive cells 
were detected in the ipsilateral OB, AON and FC after injection of 
monomers, oligomers and fibrils 72 h after injection, and those cells 
exhibit a microglia-like morphology. On the contrary, no BSA-posi-
tive cell was found in the brain 72 h after tBSA injection in the OB. 
Scale bar represents 25 μm
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Fig. 7  Tα-syn is localized within microglia 12 h after injection 
into the OB. Sections were stained by immunofluorescence for Iba1 
(green), a microglial marker. Tα-syn and tBSA were identified by 
their ATTO-550 fluorescent tag (red). Confocal three-dimensional 
reconstructions show ATTO-550 signal (red) colocalized with Iba1 
(green) within microglia in the OB of mice injected with monomers 
(a), oligomers (b) and fibrils (c), indicating that these microglial cells 
contain huα-syn. We also detected ATTO-550 signal in Iba1-positive 
cells in mice injected with the control protein tBSA (d). Scale bars 
represent 10 μm in each panel













































Fig. 8  Tα-syn is localized within microglia already 1.5 h after injec-
tion into the OB. Tα-syn was identified by its ATTO-550 fluorescent 
tag (red), and microglial cells by Iba1 staining (green) by confocal 
microscopy. At 20 min after injection of oligomers, no Iba1-positive 
cell containing ATTO-550 signal was detected (a). After 1.5 h, con-
focal three-dimensional reconstructions show ATTO-550 signal (red) 
colocalized with Iba1 (green) also within microglia in the OB of mice 
injected with oligomers at 1.5 h (b), 3 h (c) and 72 h (d) timepoints, 
indicating that these cells contain huα-syn. Scale bars represent 
10 μm in each panel
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located in these aforementioned regions (AON, FC, PC, 
OTu, TT) is plausible.
We also found labeled protein in two brain regions that 
do not project to the OB, i.e. the amygdala and striatum. 
The huα-syn in the amygdala could be the result of direct 
retrograde transport from the accessory OB along axons 
originating in the amygdala [53]. Alternatively, the huα-
syn underwent retrograde transport from the OB to, e.g. the 
ipsilateral FC and transcended one synapse before undergo-
ing further retrograde transport to the amygdala [40]. Thus, 
for all the structures cited above, both anterograde or/and 
retrograde transport(s) are conceivable. In some cases, 
the locations in which we found huα-syn require that the 
protein had transcended at least one synapse. The huα-syn 
we found in the striatum cannot be the result of retrograde 
transport due to the lack of direct (or indirect) projections 
from the striatum to the OB. Thus, if and intra-axonal 
transport to the striatum occurred, it can only be via antero-
grade transport with a transsynaptic step before reaching 
striatal neurons.
Finally, the entorhinal cortex, which receives direct 
projections from the OB, did not contain any huα-syn-
positive cells. The transfer to the entorhinal cortex might 
require more than 1.5 h considering the long distance 
between the entorhinal cortex and the OB, and transferred 
protein may be cleared from the cells before the next (3 h) 
time point we studied. Another explanation could be that 
the concentration of transferred huα-syn might be below 
DAB staining threshold. Alternatively, huα-syn may be 
either taken up inefficiently by neurons from the entorhi-
nal cortex.
Speed of α-synuclein spread is compatible  
with intra-axonal transport
At 1.5 h after injection into the OB, we observed huα-syn 
in structures located at 4.8 mm maximum distance from the 
posterior limit of injected area in the OB (maximal speed 
3.2 mm/h). At 20 min after injection, huα-syn reaches areas 
located less than 0.6 mm approximately caudal to the dif-
fusion area in the OB (maximal speed 1.8 mm/h). From 
the perspective of axonal transport, this range of speeds 
is compatible with both retrograde (4–8 mm/h) and fast 
anterograde transport (2.1–16.6 mm/h) (reviewed in [10, 
51, 55]. In fact, 15–26 % of slow component b particles 
and α-syn can be transported via fast axonal transport [36, 
56], and thus might account for the presence of huα-syn in 
structures that are relatively distant from the OB.
rapid disappearance of injected α-synuclein from neurons
At 3 h after injection, no additional (compared to the 1.5 h 
time point) brain regions contained huα-syn. In some of the 
structures where the staining obtained 1.5 h after injection 
was very discrete, it had disappeared at the 3 h time point. 
At that time, no huα-syn was detectable in the amygdala, 
striatum and brain regions further downstream. At 12 h, 
but not at 72 h a few huα-syn-positive neurons were still 
present in OBs injected with oligomers and fibrils. Inter-
estingly, we also detected huα-syn-positive microglia in 
the OB, AON and FC. These were rare at 1.5 and 3 h, but 
prevalent at 12 and 72 h. Taken together, these data sup-








First order projections from the OB
Projections to the OB
Secondary order projections 
Third order projections 
positive cells at 1.5 hour
Injection site
Fig. 9  Schematic diagram 
summarizing both the olfactory 
neural network and regions 
where huα-syn-positive cells are 
detected after injection into the 
OB. This schematic horizontal 
section of the brain illustrate 
some of the important regions 
connected to the OB. Red, 
green, yellow and blue path-
ways schematically represent 
connections within the olfactory 
system. Circular endpoint of 
pathways represents the cell 
body of a relay neuron and a 
strait end represents the axonal 
terminal. Structures filled with 
grey represent regions that 
displayed huα-syn-positive cells 
1.5 h after injection of mono-
meric and oligomeric tα-syn. 
All those regions are directly, 
or indirectly connected to the 
OB by centrifugal or centripetal 
projections
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neurons. It is likely that huα-syn is released to the extra-
cellular space by neurons, or that some neurons containing 
huα-syn died, leading to the huα-syn (free or bound to cel-
lular debris) being cleared by microglia [42].
relevance of α-synuclein transfer to the spread of lewy 
pathology in patients
regarding the spatial evolution of lewy pathology in PD 
brains, Braak and co-workers [6, 8] proposed that synu-
cleinopathy starts in the OB and AON, and/or in the dorsal 
motor nucleus of the vagus nerve; and then spreads to oth-
ers structures along neural connections [6–8, 31, 32].
The first hints that such a progression of neuropathol-
ogy is plausible are now coming from animal models of 
PD. For example, Ulusoy et al. [60] recently reported 
caudo-rostral spreading of α-syn in the medulla oblon-
gata following injection of adeno-associated viral vector 
expressing huα-syn into the vagus nerve. Moreover, luk 
et al. [43] recently demonstrated in mice that injections of 
pathologically misfolded α-syn into the striatum induce a 
PD-like pathology in different brain regions, along with 
motor dysfunction and dopaminergic nigral cell loss. The 
pathology took months to develop and was initiated by 
injecting huα-syn in the striatum, i.e. a brain structure 
that is not affected early in PD. Importantly, we investi-
gated in a very short time-frame, the transfer of huα-syn 
itself, from the OB, which is thought to be one of the two 
regions affected first in PD, to other brain regions [6, 8]. 
We know now that huα-syn can be transferred from the OB 
of WT mice to interconnected regions, within a very short 
time frame and is cleared very efficiently, presumably by 
microglia. Although others have found that certain forms of 
preformed α-syn fibrils can trigger a PD-like pathology in 
mouse brain [43, 44, 46], we saw no lewy-like bodies after 
injecting our huα-syn fibrils into the OB. Differences in the 
dose and the nature of the injected form of α-syn, e.g. mon-
omers vs oligomers vs fibrils, as well as differences in the 
duration of the experiment, could explain why we did not 
observe the formation of lewy-like bodies. Alternatively, 
the mouse OB might handle α-syn fibrils differently to the 
striatum. Interestingly, the role of α-syn oligomers in PD is 
also highly debated [38, 39], and some recent studies sug-
gest that this form of α-syn is particularly toxic [19, 23, 63] 
and plays a key intermediary role in α-syn fibrillization [3]. 
A recent paper suggests that specifically α-syn oligomers, 
but not monomers and fibrils, disturb membrane traffick-
ing when cultivated cells are exposed to them in the cul-
ture medium [13]. With this background, the high propen-
sity of oligomers to spread between brain regions, which 
we observed in our model, may be important also in a dis-
ease context. We observed that monomeric and oligomeric 
α-syn can be transferred to interconnected regions. From 
that, we can speculate that a pathological seed of α-syn in 
the same range of size as our monomers–oligomers could 
also be transferred in an identical manner to interconnected 
regions. Moreover, if the α-syn escapes from proteostatic 
clearance, it can slowly recruit other proteins (including α-
syn from the recipient cell) and thereby contribute to the 
spread of synucleinopathy within the brain.
Conclusion
We have demonstrated for the first time that huα-syn 
injected into the OB is taken up by neurons and transferred 
to interconnected brain regions. This transfer is consist-
ent with anterograde and/or retrograde axonal transport as 
well as cell-to-cell transfer. Our data support the concept 
that α-syn (main component of lewy bodies) can spread 
from the OB, one of the first structures affected in PD 
according to Braak and collaborators, to interconnected 
brain regions.
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